Lessons From Biotech Entrepreneurs: Pitching Your First-In-Class Innovation
Scientific Leaders From Nurix, Arrakis And Strand Therapeutics On Hitting ‘Undruggable’ Targets
The role of biopharma start-ups in bringing innovative therapies to the market has grown enormously. These waves of new specialist companies often have the most innovative approaches to targeting a disease, and big pharma has become increasingly reliant on their fresh ideas to power pipelines.
You may also be interested in...
After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.
GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.